Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H1 2018 - Product Image

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H1 2018

  • ID: 4516005
  • Report
  • 121 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Argos Therapeutics Inc
  • e-Therapeutics Plc
  • F. Hoffmann-La Roche Ltd
  • Invectys SA
  • Johnson & Johnson
  • Telocyte LLC
  • MORE
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H1 2018

Summary:

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) pipeline Target constitutes close to 32 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes.

The latest report Telomerase Reverse Transcriptase - Pipeline Review, H1 2018, outlays comprehensive information on the Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. It modulates Wnt signaling. It plays important role in aging and anti-apoptosis.

The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 2, 1, 10 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Hematological Disorders, Immunology, Male Health, Metabolic Disorders and Respiratory which include indications Alzheimer's Disease, Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Solid Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Aplastic Anemia, Atherosclerosis, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Cervical Cancer, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Gastroesophageal (GE) Junction Carcinomas, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Idiopathic Pulmonary Fibrosis, Leukemias, Lung Adenocarcinoma, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Muscle Invasive Bladder Cancer (MIBC), Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Premature Ageing, Renal Cell Carcinoma, Small-Cell Lung Cancer and Squamous Non-Small Cell Lung Cancer.

Furthermore, this report also reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)
  • The report reviews Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Argos Therapeutics Inc
  • e-Therapeutics Plc
  • F. Hoffmann-La Roche Ltd
  • Invectys SA
  • Johnson & Johnson
  • Telocyte LLC
  • MORE
Introduction

Report Coverage

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Overview

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Companies Involved in Therapeutics Development

Argos Therapeutics Inc

Asterias Biotherapeutics Inc

e-Therapeutics Plc

F. Hoffmann-La Roche Ltd

Inovio Pharmaceuticals Inc

Invectys SA

Johnson & Johnson

Komipharm International Co Ltd

Mediolanum farmaceutici SpA

Telocyte LLC

TILT Biotherapeutics Ltd

Ultimovacs AS

Vaxon Biotech

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drug Profiles

AGS-499 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Gene Therapy to Inhibit Telomerase Reverse Transcriptase for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASTVAC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASTVAC-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dendritic Cell Therapy + TILT-234 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETS-2300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Telomerase for Alzheimer's Disease and Pulmonay Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Telomerase for Alzheimer’s Disease and Atherosclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate TERT for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GX-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imetelstat sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-1400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INVAC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KML-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ribovax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rocapuldencel-T - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Telomerase for Lung Cancer and Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Telomerase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

telin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tertomotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCPVax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UV-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Telomerase for Cervical Cancer and Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-026 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vx-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vx-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Dormant Products

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Discontinued Products

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Product Development Milestones

Featured News & Press Releases

Mar 24, 2018 : New Preclinical Data for THIO in BRAF-Mutant Mouse Melanoma Models

Jan 30, 2018 : CNIO researchers cure lung fibrosis in mice with a gene therapy that lengthens telomeres

Jan 04, 2018 : Asterias Biotherapeutics Provides Update on ASTVAC-

Dec 19, 2017: PharmaJet and Invectys Partner in Phase II Clinical Trial of DNA Cancer Vaccine

Dec 12, 2017: Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting

Nov 27, 2017: Inovio Pharmaceuticals SynCon TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model

Nov 20, 2017: Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes

Nov 11, 2017: Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting

Nov 10, 2017: Inovio Pharmaceuticals Presents data on INO-1400 at Society for Immunotherapy of Cancer Conference

Nov 06, 2017: Argos Announces Receipt of Milestone Payment from Lummy

Nov 01, 2017: Janssen to Present Abstracts on Imetelstat at ASH 2

Nov 01, 2017: Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regenerons PD-1 Inhibitor

Oct 31, 2017: Geron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes

Sep 26, 2017: Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VAC2 in Subjects with Early and Late Stage Non-Small Cell Lung Cancer

Sep 19, 2017: Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Argos Therapeutics Inc, H1 2018

Pipeline by Asterias Biotherapeutics Inc, H1 2018

Pipeline by e-Therapeutics Plc, H1 2018

Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Pipeline by Inovio Pharmaceuticals Inc, H1 2018

Pipeline by Invectys SA, H1 2018

Pipeline by Johnson & Johnson, H1 2018

Pipeline by Komipharm International Co Ltd, H1 2018

Pipeline by Mediolanum farmaceutici SpA, H1 2018

Pipeline by Telocyte LLC, H1 2018

Pipeline by TILT Biotherapeutics Ltd, H1 2018

Pipeline by Ultimovacs AS, H1 2018

Pipeline by Vaxon Biotech, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

Discontinued Products, H1 2018

Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Argos Therapeutics Inc
  • Asterias Biotherapeutics Inc
  • e-Therapeutics Plc
  • F. Hoffmann-La Roche Ltd
  • Inovio Pharmaceuticals Inc
  • Invectys SA
  • Johnson & Johnson
  • Komipharm International Co Ltd
  • Mediolanum farmaceutici SpA
  • Telocyte LLC
  • TILT Biotherapeutics Ltd
  • Ultimovacs AS
  • Vaxon Biotech
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll